Abcam PLC (ABCM)
| Market Cap | 4.73B |
| Revenue (ttm) | 329.11M |
| Net Income (ttm) | 15.82M |
| Shares Out | 226.72M |
| EPS (ttm) | 0.08 |
| PE Ratio | 279.92 |
| Forward PE | 91.74 |
| Dividend | $0.15 |
| Dividend Yield | 0.71% |
| Trading Day | May 7 |
| Last Price | $21.26 |
| Previous Close | $20.75 |
| Change ($) | 0.51 |
| Change (%) | 2.46% |
| Day's Open | 20.80 |
| Day's Range | 20.70 - 21.32 |
| Day's Volume | 222,394 |
| 52-Week Range | 17.88 - 24.69 |
CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (...
CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to...
CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Resea...
CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, to...
CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China...
CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its ...
CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Hea...
Abingdon Health signs collaboration and co-marketing agreement with Abcam
CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appo...
Abcam has a strong position in the niche of supplies for antibody research. It is profitable, dividend paying, and continues to grow well.
CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 Se...
CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation wit...
About ABCM
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex as... [Read more...]
| Industry Biotechnology | IPO Date Oct 22, 2020 |
| CEO Murray Hennessy | Employees 1,600 |
| Stock Exchange NASDAQ | Ticker Symbol ABCM |
Financial Performance
In 2020, Abcam PLC's revenue was 260.00 million, an increase of 0.04% compared to the previous year's 259.90 million. Earnings were 12.50 million, a decrease of -72.22%.
Analyst Forecasts
According to 2 analysts, the average rating for Abcam PLC stock is "Buy." The 12-month stock price forecast is 1,606.37, which is an increase of 7,455.83% from the latest price.